Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7NTN

The structure of RRM domain of human TRMT2A at 2 A resolution

Summary for 7NTN
Entry DOI10.2210/pdb7ntn/pdb
DescriptortRNA (uracil-5-)-methyltransferase homolog A, SULFATE ION, CHLORIDE ION, ... (5 entities in total)
Functional Keywordstrna binding, methyltransferase, trmt2a, polyq aggregation, transferase
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight9727.40
Authors
Davydova, E.,Janowski, R.,Witzenberger, M.,Niessing, D. (deposition date: 2021-03-10, release date: 2022-01-19, Last modification date: 2024-06-19)
Primary citationMargreiter, M.A.,Witzenberger, M.,Wasser, Y.,Davydova, E.,Janowski, R.,Metz, J.,Habib, P.,Sahnoun, S.E.M.,Sobisch, C.,Poma, B.,Palomino-Hernandez, O.,Wagner, M.,Carell, T.,Jon Shah, N.,Schulz, J.B.,Niessing, D.,Voigt, A.,Rossetti, G.
Small-molecule modulators of TRMT2A decrease PolyQ aggregation and PolyQ-induced cell death.
Comput Struct Biotechnol J, 20:443-458, 2022
Cited by
PubMed Abstract: Polyglutamine (polyQ) diseases are characterized by an expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats encoding for an uninterrupted prolonged polyQ tract. We previously identified TRMT2A as a strong modifier of polyQ-induced toxicity in an unbiased large-scale screen in . This work aimed at identifying and validating pharmacological TRMT2A inhibitors as treatment opportunities for polyQ diseases in humans. Computer-aided drug discovery was implemented to identify human TRMT2A inhibitors. Additionally, the crystal structure of one protein domain, the RNA recognition motif (RRM), was determined, and Biacore experiments with the RRM were performed. The identified molecules were validated for their potency to reduce polyQ aggregation and polyQ-induced cell death in human HEK293T cells and patient derived fibroblasts. Our work provides a first step towards pharmacological inhibition of this enzyme and indicates TRMT2A as a viable drug target for polyQ diseases.
PubMed: 35070167
DOI: 10.1016/j.csbj.2021.12.029
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.016 Å)
Structure validation

227344

건을2024-11-13부터공개중

PDB statisticsPDBj update infoContact PDBjnumon